A peptide inhibitor called RI-AG03 targets major aggregation “hot spots” of tau proteins, believed to be a key driver of Alzheimer’s disease.

“This research is taking promising steps towards a new one-of-a-kind therapy which targets tau, a damaging protein in the brains of people living with Alzheimer’s, preventing it from clumping together,” said Richard Oakley, associate director of research and innovation at the Alzheimer’s Society UK, which funded the research.

Scientists say they have achieved a "first" in the development of drugs to treat Alzheimer's disease. In a study published in the journal Alzheimer's & Dementia, a team of researchers report the development of a new compound that they say is a "promising" candidate in the search for new therapies for neurodegenerative diseases,

Researchers have hailed a promising breakthrough in the development of drugs to treat Alzheimer’s disease. For the first time, scientists have created a drug that works by targeting both key areas of a protein linked to the disease.